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undergone emergent CABG, other type or surgery and coronary angioplasty with CABG were excluded. No power calculations to determine the sample size were conducted.
Study design
This was a retrospective multi-centre cohort study carried out using data from the Solucient EXPLORE database.
Analysis of effectiveness
The primary health outcomes used in the study were the in-hospital mortality rates, length of stay, number of deaths avoided, number of transfers, and the number of patients needed to transfer to avoid a death. The groups were stated to have been comparable in terms of age and gender.
The predicted risks of in-hospital mortality for each patient included in the study were calculated using a logistic regression model. The predictors used for CABG-related in-hospital mortality were age, gender, surgical priority and severity of illness. The patients were divided into five groups according to the likelihood of suffering in-hospital mortality. Based on this risk model, 7,047 patients were classified as minimal risk (51.7%), 4,409 as low risk (32.3%), 1,273 as moderate risk (9.3%), and 461 as high risk (3.4%).
The Hosmer-Lemeshow goodness-of-fit statistic was used to establish goodness-of-fit in the model. Model discrimination was measured using the C-index. Differences between in-hospital mortality rates were assessed using chi-squared tests. Variance estimates were used to adjust for the potential effects of clustering at the hospital level.
Effectiveness results
The authors observed a significant difference with respect to in-hospital mortality rates between low-and high-volume hospitals, 3.3% (low-volume) versus 1.9% (high-volume), (p=0.001). Patients at low-volume centres (with less than 200 CABG/year) presented a longer in-hospital length of stay in relation to patients from high-volume centres (more than 200 CABG/year), 8.5 (+/-0.27) days versus 7.8 (+/-0.32) days, (p=0.09).
With respect to the different risk groups, the study showed significant differences between low-and high-volume centres for patients at moderate and high risk. The in-hospital mortality rates were 5.3% (low-volume) versus 2.2% (high-volume) for moderate-risk patients, and 22.6% (low-volume) versus 11.9% (high-volume) for high-risk patients, (p=0.026). For low-risk patients, the in-hospital mortality rate in low-volume hospitals was slighter higher (1.7%) than in high-volume centres (1.0%), but not statistically significant, (p=0.19). The authors observed no statistically significant differences in in-hospital mortality for those patients with minimal or severe risk.
The authors did not find any statistically significant difference in relation to the length of stay between the two types of centres. If a policy of full regionalisation was implemented (transferring all type of patients from a low-to a highvolume centre), 2,029 transfers would have to take place and 20 deaths would be avoided, with 101 patients requiring a transfer to avoid one death. If a strategy of targeted regionalisation was implemented (transferring moderate-or highrisk patients from low-to high-volume centres), there would have been 370 transfers and 16 avoided deaths, with 23 patients requiring transfer to avoid one death. Targeted regionalisation (low risk and above) would have led to 1,083 transfers and 20 deaths avoided, with 54 patients requiring a transfer to avoid one death.
Clinical conclusions
There were no statistically significant differences in the in-hospital mortality rates between the two types of centres (low-and high-volume) in patients at minimal or moderate surgical risk. Full regionalisation (transfer of all type of patients from a low-volume centre) may result in little or no benefit when the number of patients classified in the group of minimal to moderate risk is high (84%). For patients with moderate to high risk, the in-hospital mortality in low-volume centres is two-fold greater than in high-volume hospitals. Targeted regionalisation strategies, which focus on identifying high-risk patients and referring them to high-volume centres, may be as effective as full regionalisation strategies.
Measure of benefits used in the economic analysis
There was no summary measure of benefit. A cost-consequences analysis was therefore conducted.
Direct costs
The hospital costs were calculated using a comparative costing methodology, and standardised across centres using a two-tiered method. The authors did not apply discounting. However, although not stated it appeared that the costs were incurred during a one-year period and, consequently, discounting would not have been required. The quantities were not reported separately from the costs, and the study did not report which quantities or costs were measured. No price year was reported.
Statistical analysis of costs
The differences in the hospital costs and length of stay were assessed using Student's t-test. Due to a highly skewed distribution, logarithmic transformations were performed prior to the statistical analyses. This type of transformation was justified given the properties of the distribution.
Indirect Costs
The authors stated that the indirect hospital costs were included for each patient. However, they did not report which quantities or costs were measured.
Currency

US dollars $.
Sensitivity analysis
The only sensitivity analysis conducted was on the volume threshold variable. This was varied between the ranges of 100 to 300 annual cases.
Estimated benefits used in the economic analysis
No summary benefit measure was used. See the 'Effectiveness Results' section.
Cost results
The general costs at low-volume hospitals for patients undergoing CABG appeared to be greater than those at highvolume centres, $21,611 (+/-$1,043) versus $19,090 (+/-$1,265), (p=0.052).
No statistically significant differences in hospital costs were found across the risk groups. For patients classified at minimal risk, the mean low-volume hospital costs were $16,700 (95% confidence interval, CI: 15,500 -18,000) whereas the mean high-volume hospital cost were $15,400 (95% CI: 14,500 -16,400), (p=0.18). For low-risk patients, the mean hospital costs in low-volume centres were slightly higher ($20,400, 95% CI: 18,500 -23,400) than in highvolume centres ($18,000, 95% CI: 16,900 -19,300), (p=0.09). For the other risk groups, the differences observed between the mean costs were not statistically significant
Synthesis of costs and benefits
Not relevant as a cost-consequences analyses was conducted.
Authors' conclusions
In patients with moderate or high surgery risk, the in-hospital mortality rates for CABG differed for low-and highvolume hospitals. No differences in in-hospital mortality were observed in patients with low or minimal risks. After
